已收盤 07-14 16:00:00 美东时间
0.000
0.00%
Indutrade AB ( ($SE:INDT) ) just unveiled an update. Indutrade AB has acquired ...
10-02 16:03
Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to 17.5 years) with Prader-Willi Syndrome under a cleared INDTNX-2900 granted Orphan Drug and Rare Pediatric Disease Designations by the FDA, providing the potential for a Priority Review Voucher upon approval
09-29 19:08
Indutrade AB ( ($SE:INDT) ) has provided an update. Indutrade AB has announced ...
09-16 15:09
Indutrade AB ( ($SE:INDT) ) has provided an announcement. Indutrade AB has anno...
09-15 15:09
Indaptus Therapeutics CEO Jeffrey Meckler will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:30 PM ET in Kennedy I (4th Floor), Lotte New York Palace Hotel. A live webcast will be available on the company's investor relations website, with a replay archived for 90 days. Meckler will discuss the company's innovative immunotherapy platform, which uses a multi-targeted approach to activate immune ...
09-02 20:05
Indutrade AB ( ($SE:INDT) ) has issued an update. Indutrade AB has acquired Uto...
07-09 15:01
INDUS Realty Trust, Inc. (NASDAQ:INDT) ("INDUS" or the "Company") a U.S.-based industrial/logistics REIT, announced that it has received written notice from the Committee on Foreign Investment in the United States
2023-06-23 20:35
Tuesday marks the last chance for investors to receive the next dividend payout...
2023-06-16 22:45
Citigroup analyst Emmanuel Korchman maintains INDUS Realty Trust (NASDAQ:INDT) with a Neutral and raises the price target from $65 to $67.
2023-05-10 20:49
INDUS Realty Trust (NASDAQ:INDT) reported quarterly earnings of $0.51 per share. This is a 34.21 percent increase over earnings of $0.38 per share from the same period last year. The company reported $13.57 million in
2023-05-04 05:09